alpha-aminopyridine has been researched along with Mesothelioma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anthony, S; Bajaj, A; Bhundia, V; Branson, A; Brookes, C; Darlison, L; Dawson, AG; Fennell, DA; Gaba, A; Greystoke, A; Hutka, M; King, A; Mohammed, S; Morgan, B; Nusrat, N; Poile, C; Richards, C; Scotland, M; Thomas, A; Wells-Jordan, P | 1 |
| Aerts, JG; Bezemer, K; Dammeijer, F; Hegmans, JP; Hendriks, RW; Kaijen-Lambers, ME; Lievense, LA; van Hall, T; van Nimwegen, M | 1 |
| Arkenau, HT; Auger, KR; Blagden, SP; Fleming, RA; Gazzah, A; Greystoke, A; Mak, G; Mazumdar, J; Nebot, N; Plummer, R; Rizzuto, I; Rogan, D; Soria, JC; Tolson, J; Yan, L; Zhang, J | 1 |
| Dhanasingh, I; Kanteti, R; Kindler, HL; Lennon, FE; Mambetsariev, B; Mirzapoiazova, T; Riehm, JJ; Salgia, R | 1 |
2 trial(s) available for alpha-aminopyridine and Mesothelioma
| Article | Year |
|---|---|
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Topics: Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Diarrhea; Hemoptysis; Humans; Mesothelioma; Mesothelioma, Malignant; Pleural Neoplasms; Pulmonary Embolism; Respiratory Tract Infections; Sepsis; Thrombocytopenia; Vomiting | 2022 |
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
Topics: Aged; Aminopyridines; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hydroxamic Acids; Male; Mesothelioma; Middle Aged; Neoplasms; Progression-Free Survival; Pyridones; Pyrimidinones | 2019 |
3 other study(ies) available for alpha-aminopyridine and Mesothelioma
| Article | Year |
|---|---|
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
Topics: Aminopyridines; Animals; Antigens, Neoplasm; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Macrophages; Mesothelioma; Mesothelioma, Malignant; Neoplasm Invasiveness; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor | 2017 |
FAK inhibitor kills mesothelioma cells.
Topics: Aminopyridines; Focal Adhesion Protein-Tyrosine Kinases; Humans; Mesothelioma; Protein Kinase Inhibitors | 2014 |
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crizotinib; Drug Synergism; Female; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; Microtubules; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |